Seth T. Gammon

This paper develops a monoclonal antibody targeting 4Ig-B7-H3 for beta-radioligand therapy, showing improved tumor-specific binding and immune priming effects in preclinical models.

This study develops hyperpolarized silicon particles functionalized with MUC1 antibody for targeted molecular MRI of colorectal cancer, showing active tumor targeting in vivo.

This study identifies statins as inhibitors of 4Ig-B7-H3 dimerization, linking their anti-cancer effects to immune checkpoint disruption in B7-H3-expressing tumors.

This study shows that ACL loss in the heart increases glucose oxidation and reduces citrate efflux, leading to metabolic remodeling and cardiac dysfunction.